^
Association details:
| Biomarker: | EGFR G719X |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
Excerpt:
...Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, E709X, etc., S768I in exon 20 and at least one of the L861Q mutations in exon 21; 4....
Trial ID:
Source:
Title:
Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial
Published date:
10/12/2022
Excerpt:
Eligible patients had EGFR exon 18-mutant NSCLC and ECOG performance status 0–2....Patients received neratinib (240 mg po daily)....ORR was 31% overall and 26% in patients pretreated with TKIs (Table 1). Two of 7 patients with baseline CNS metastasis had a partial response (PR; median PFS 3.6 months; 95% CI 1.9–9.1 months). Long-lived responses were observed in 3 patients with G719A/X/C mutations (2 PR, 1 SD)....Neratinib monotherapy had meaningful activity in patients with EGFR exon 18-mutant NSCLC in SUMMIT; 31% of patients had a PR and most patients had prior TKIs.
Trial ID:
